Physician profile
Mirna Farhat
NPI 1669703781
$6,964.39
in general payments reported to CMS, 2019-2025
50 companies · $2,470 in 2025
The $2,470 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $162 · 2021: $329 · 2022: $654 · 2023: $1,072 · 2024: $2,046 · 2025: $2,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,782 · Education: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,781.98 |
| Education | $805.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $554.27 | 2024-2025 | Erleada, Rybrevant, Imbruvica |
| Daiichi Sankyo INC. | $447.58 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Novartis Pharmaceuticals Corporation | $415.98 | 2021-2025 | |
| Genentech USA, INC. | $415.47 | 2021-2025 | Perjeta, Phesgo, Kadcyla |
| Celgene Corporation | $365.52 | 2019-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $308.52 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| E.R. Squibb & Sons, L.L.C. | $306.53 | 2020-2025 | Opdualag, Opdivo |
| Astrazeneca Pharmaceuticals LP | $289.66 | 2024-2025 | Enhertu, Imfinzi, Tagrisso |
| Abbvie INC. | $266.05 | 2022-2025 | |
| Sobi, INC | $262.83 | 2022-2025 | |
| Eisai INC. | $248.31 | 2021-2024 | |
| Gilead Sciences, INC. | $210.25 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $183.01 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $181.86 | 2024-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $177.74 | 2019-2025 | Verzenio, Jaypirca |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $153.64 | 2019-2024 | Xarelto |
| Jazz Pharmaceuticals INC. | $149.89 | 2021-2024 | |
| Astellas Pharma US INC | $139.03 | 2023-2025 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $137.44 | 2019-2025 | Keytruda, Welireg |
| Pfizer INC. | $135.00 | 2022-2025 | |
| Glaxosmithkline, LLC. | $133.94 | 2023-2025 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $130.50 | 2022-2025 | Libtayo, Lynozyfic |
| Karyopharm Therapeutics INC. | $120.15 | 2024-2025 | Xpovio |
| Exelixis INC. | $115.88 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.32 | 2020-2025 | Ninlaro, Fruzaqla |
| Seagen INC. | $113.57 | 2022-2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $101.06 | 2025 | |
| Beigene USA, INC. | $62.14 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $60.56 | 2022-2023 | Imbruvica |
| Amgen INC. | $51.07 | 2021-2022 | |
| Pharmaessentia USA Corporation | $50.81 | 2023-2025 | Besremi |
| Blueprint Medicines Corporation | $48.79 | 2023-2025 | Ayvakit |
| Beone Medicines USA, INC. | $47.95 | 2025 | Brukinsa |
| Emd Serono, INC. | $45.60 | 2019-2024 | Bavencio |
| Janssen Scientific Affairs, LLC | $43.10 | 2025 | Erleada, Balversa |
| Puma Biotechnology, INC. | $38.24 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $36.36 | 2023-2024 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $33.77 | 2021 | |
| Array Biopharma INC | $32.95 | 2025 | Braftovi, Lorbrena, Mektovi |
| Alnylam Pharmaceuticals INC. | $29.05 | 2024 | Amvuttra |
| Tempus Ai, INC | $28.63 | 2024 | |
| Apellis Pharmaceuticals, INC. | $25.49 | 2024 | Empaveli |
| Sirtex Medical INC | $24.09 | 2022 | |
| Novocure INC. | $21.80 | 2025 | Optune Lua (Novottf-200t) |
| Btg International INC. | $20.12 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2022 | |
| Azurity Pharmaceuticals, INC. | $16.79 | 2025 | Danziten |
| Pharmacosmos Therapeutics INC. | $16.74 | 2024 | Monoferric |
| Stemline Therapeutics INC. | $16.33 | 2023 | Orserdu |
| Kite Pharma, INC. | $16.11 | 2023 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirna Farhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.